Study wrapper · #976
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
Garvey WT, Blüher M, Osorto Contreras CK, et al. The New England journal of medicine. 2025.
DOI: 10.1056/nejmoa2502081PubMed: 40544433
Editor's note
The pivotal REDEFINE 1 phase 3a trial (3417 participants, 68 weeks) reporting a mean weight change of -20.4% with cagrilintide-semaglutide versus -3.0% with placebo. Gastrointestinal adverse events were common but mostly mild-to-moderate and transient. High-quality primary human evidence directly on both tracked peptides.
Plain-language abstract
In this phase 3 trial, cagrilintide-semaglutide was associated with about 20% body-weight reduction versus 3% with placebo in adults with overweight or obesity.
Related coverage
Mixed
Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
Lancet (London, England)n=——2026
Supported
Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding.
Physiology & behaviorn=——2026
Supported
Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials.
Naunyn-Schmiedeberg's archives of pharmacologyn=——2026